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CASE REPORT Open Access
Limited efficacy of adalimumab in the
acute phase of serpiginous choroiditis
refractory to corticosteroid and
cyclosporine, a case report
Kazunori Noda, Akio Oishi*, Akihito Uji, Saori Tanaka and Akitaka Tsujikawa
Abstract
Background: The optimal treatment of serpiginous choroiditis is not established. While recent reports indicate the
efficacy of adalimumab, there is limited evidence. We present a case of serpiginous choroiditis refractory to steroids,
immunosuppressants, and adalimumab.
Case presentation: An 18-year-old woman presented with severe vision loss in both eyes. A fundus examination
revealed a foveal grayish-white lesion, and optical coherence tomography revealed outer retinal damage. She was
diagnosed with serpiginous choroiditis and treated with steroid pulse therapy, but the disease progressed
continuously. The addition of sub-Tenon’s injection of triamcinolone and oral cyclosporine did not change the
disease course. We also administered subcutaneous injections of adalimumab, but even with the intensive
treatment, the retinal lesions and subsequent atrophy progressed. Her right and left visual acuity declined from 20/22
to 20/66 and 20/200, respectively, during the 9months of follow-up.
Conclusion: Here, we report a case of serpiginous choroiditis refractory to corticosteroids, immunosuppressants, and
adalimumab. Further studies are needed to establish the optimal treatment for such cases.
Keywords: Serpiginous choroiditis, Chorioretinal degeneration, Geographic choroiditis, Geographic choroidopathy,
Posterior uveitis, Relentless placoid chorioretinitis, Serpiginous choroidopathy
Background
Serpiginous choroiditis was first described in 1932 by Ju-
nius as “peripapillary retinochoroiditis,” after which there
were various designations and reports on the subtypes [1].
The disease is characterized by bilateral, chronic, progres-
sive, and recurrent inflammation of the choroid, chorioca-
pillaris, and retinal pigment epithelium [1, 2]. The disease
is prevalent in healthy, young to middle-aged adults
irrespective of race [1]. Infectious diseases such as tuber-
culosis may present serpiginous-like choroiditis and must
be ruled out. The optimal treatment is yet to be estab-
lished because of the rarity and unknown etiology of the
disease. Corticosteroids and immunosuppressants, such as
cyclosporine and azathioprine, are commonly prescribed.
Recently, some reports showed the efficacy of biological
drugs such as infliximab [3] and adalimumab [4, 5] and
intravenous pulse cyclophosphamide therapy [6]. How-
ever, these are single case reports, so the efficacy of the
drugs may have been overestimated. In this paper, we
present a case of serpiginous choroiditis refractory to
adalimumab, corticosteroids, and cyclosporine.
Case presentation
An 18-year-old woman was referred to our hospital with
the complaint of central visual field defect in the right
eye for 1 week and in the left eye for 3 days.
Her medical history was unremarkable except for
pediatric asthma and appendicitis. She reported no raw
meat consumption and had a dog until a year ago.
She received vaccination for human papillomavirus 3
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years ago. The best corrected visual acuity was 20/22
in both eyes.
The anterior segment examination was unremarkable in
both eyes. The fundus examination showed bilateral
grayish-white retinal lesions around the macula, and the
optical coherence tomography showed corresponding
hyperreflectivity and thinning of the outer retina (Fig. 1).
The features of tuberculous serpiginous-like choroiditis
such as vitreous hyper-reflective spots, intraretinal edema,
sub-retinal pigment epithelium drusenoid deposits, and
Fig. 1 Fundus photograph (a and c) and optical coherence tomography (OCT) images (b and d) of an 18-year-old patient with serpiginous choroiditis. A
grayish-white exudative lesion is observed in the macula area. The corresponding OCT image shows a hyperreflective appearance in the outer retina
Fig. 2 Fluorescein and indocyanine angiography (FA and ICGA in the left and right panels, respectively) images of the patient. On FA, the lesion
appeared hypofluorescent in the early phase (a and c) and turned hyperfluorescent in the late phase (b and d). Meanwhile, ICGA showed a
hypofluorescent appearance in both the phases
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choroidal granulomas were not present [7]. The lesion
was hypofluorescent and hyperfluorescent in the early
and late phases, respectively, on fluorescein fundus
angiography (FA). The lesion was hypofluorescent from
the early to late phase on indocyanine green angiog-
raphy (ICGA) (Fig. 2).
The intraocular pressures were 18 and 15mmHg in
the right and left eyes, respectively.
No abnormalities were detected with blood tests
except for a mild increase of C-reactive protein (0.4 mg/
dL) and white blood cells (10,020/μL). We performed
QuantiFERON tests at the initial presentation and 2
weeks later, which showed negative results.
She was diagnosed with serpiginous choroiditis and
treated with prednisone 40mg/day.
On the 6th day, the retinal lesion was enlarged, and
the outer retinal damage had progressed (Fig. 3b). Thus,
transvenous methylprednisolone (mPSL; 1 g/day) was
administered for 3 days.
After the initiation of the steroid pulse therapy, the sub-
jective symptoms improved. However, the grayish-white
retinal lesions continued to enlarge in both eyes. The
Fig. 3 Fundus photographs and optical coherence tomography (OCT) images of a serpiginous choroiditis patient. a At initial presentation. b The
lesion enlarged despite 6 days of oral prednisone (white arrow). The corresponding OCT revealed a hyperreflective lesion in the outer retina
(black arrows). c Day 16. Even with steroid pulse therapy and sub-Tenon’s injection of triamcinolone, the lesion had continued to enlarge (white
arrow). The original lesion rapidly progressed to an atrophy. d Day 24. We started cyclosporine, but the new lesion appeared upper to the optic
disc (white arrow). The OCT showed development of the hyperreflective lesion (black arrows). e Day 41. Two weeks after the adalimumab
injection., the lesion had enlarged to reach the nose (white arrow, black arrows). f Month 9. The disease had progressed for 8 months and left a
fibrotic scar in the macula. No new lesions were observed after the 9th month
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disease progression was not controlled despite 3 more
days of mPSL (1 g/day), following 60 mg of oral pred-
nisone. Sub-Tenon’s triamcinolone acetonide injection
(20 mg) was administered to the left eye and then to
the right eye. (Fig. 3c).
We added oral cyclosporine (300 mg), and prednisone
was switched to betamethasone (7 mg). The trough
blood cyclosporin concentration was monitored and
controlled at around 200 ng/mL. While the initially
affected areas changed to atrophic scars, new lesions
appeared adjacent to or away from the initial lesion
(Fig. 3d). Subcutaneous injections of adalimumab (80
mg) were started on the 27th day, and intravitreal
injections of triamcinolone acetonide (20 mg) were
administered in the right eye on the 34th day, but
they could not stop the disease progression. Oral
cyclosporine (300 mg) and betamethasone (3 mg) and
biweekly subcutaneous injections of adalimumab (40
mg) were continued, but the retinal lesions pro-
gressed up to 8 months (Fig. 3e). Her visual acuity
declined to 20/66 and 20/200 in the right and left
eyes, respectively. Both eyes showed a similar course
during the observation period. The disease progressed
up to the 9th month, but no new lesions were ob-
served thereafter (Fig. 3f).
Discussion and conclusions
We presented a refractory case of serpiginous choroiditis.
The disease progressed for 9 months despite the use of
adalimumab. The course was inconsistent with recent
two case reports showing the efficacy of adalimumab in
serpiginous choroiditis refractory to conventional treat-
ment [3, 4]. Both studies reported favorable responses, 1
month after the adalimumab treatment [3, 4]. However,
adalimumab was used in the chronic phase in these re-
ports (about 3 and 8 years after the onset, respectively).
The progression was controlled with adalimumab after
8 months in the present case. While we cannot draw def-
inite conclusions from a single case, the effect of adali-
mumab in the acute phase of refractory serpiginous
choroiditis may not be as good as was previously re-
ported for the chronic phase. Further studies are needed
to establish the optimal treatment.
The present case indicated the utility of optical coher-
ence tomography (OCT) to monitor.
the disease progression. The lesion appeared as a
hyperreflective area in the outer retina and progressed
to retinal atrophy. The grayish-white lesion could also
be confirmed in fundus examinations, but differentiating
between the fibrotic scar and the recurred lesion was
sometimes challenging (Fig. 3f ). The OCT-based treat-
ment strategy, as established in age-related macular
degeneration, needs to be tested in future studies.
Differentiating between serpiginous choroiditis and
tuberculous serpiginous-like choroiditis is not always
easy. In the present case, the failure of response to im-
munosuppressive treatments made us re-consider tuber-
culous serpiginous-like choroiditis and other infectious
conditions. Additionally, the multifocal appearance was
suggestive of tuberculous serpiginous-like choroiditis [8].
However, the repeated QuantiFERON test results were
negative, and the OCT features reported in tuberculous
serpiginous-like choroiditis were absent in the present
case. Blood tests did not indicate other possible condi-
tions such as syphilis or herpes. Considering the side
effects of anti-tuberculous and anti-viral treatments, we
continued immunosuppression and succeeded to cease
the disease progression. A careful evaluation is necessary
in such refractory cases.
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